Based on Monoclonal Antibodies
Phase II clinical trials of BCD-085, an original drug based on monoclonal antibodies, blocking interleukin-17 have started. It is performed by biotechnological company BIOCAD in Russia and Belarus. The studies will involve 88 patients with active ankylosing spondylitis. The information to be received during clinical trials of BCD-085, it will be possible to detect which patients need the drug most, and to identify its effective and safe dose.
If the studies pass successfully, according to BIOCAD plans the drug will be launched in 2019-2020.
Currently only one monoclonal antibody against IL-17 for treatment of patients with active ankylosing spondylitis manufactured in Switzerland, is approved in Russia (secukinumab). But for most patients the original drug is too expensive. As BCD-085 is passing the whole cycle of development and manufacture in Russia, it will become affordable for a large population of patients with active ankylosing spondylitis.